Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.
Bladder cancer
Immunochemistery
Immunoscore
Prognosis
Journal
Journal of the Egyptian National Cancer Institute
ISSN: 2589-0409
Titre abrégé: J Egypt Natl Canc Inst
Pays: England
ID NLM: 9424566
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
received:
30
10
2023
accepted:
06
03
2024
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) and the derived immunoscore (IS) have gained considerable attention over the last decade as prognostic markers in many solid cancers. However, in bladder cancer (BC), their prognostic value is not clearly established. The present study aimed to quantify the TILs rates in BC, assess the derived immunoscore, and investigate their prognostic value. An immunochemistry-based quantification of the different subtypes of TILS was performed on paraffin-embedded blocks from patients with invasive urothelial carcinoma of the bladder. We have assessed the rates of TILs, respectively, on peri-tumoral (PT) and intra-tumoral (IT) areas and calculated for each case the corresponding IS which is the index: CD8+/CD3+ TILs. The IS was then classified as low (I0, I1) or high (I2, I3, I4). We included 30 cases in the analysis. The median age of patients was 65 years with a sex ratio of 9. TILs densities and distribution were significantly variable between IT and PT areas CD3+ (p = 0.03) and CD8+ (p = 0.004) with the highest rates on the PT areas. In univariate analysis, a low density of CD8+ TILs was significantly associated with an advanced age (p = 0.05), with the presence of lympho-vascular invasion (p = 0.02) and with the absence of specific histological subtype (p = 0.05). A low immunoscore was significantly associated with the presence of lympho-vascular invasion (p = 0.004). No significant association was found between TILs subpopulations, the IS, and the other clinicopathological and survival data. The overall survival (OS) and disease-free survival (DFS) medians were slightly superior in highly T (CD3+/CD8+)-cell infiltrated tumors as well as tumors with a high IS densities. However, the univariate analysis showed that TILs and immunoscore did not impact overall survival (OS) and disease-free survival (DFS). TILs and immunoscore might be effective prognostic tools in BC. However, standardized quantification methods and further investigation on larger samples are highly recommended to definitively attest the prognostic value of TILs and IS in BC.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) and the derived immunoscore (IS) have gained considerable attention over the last decade as prognostic markers in many solid cancers. However, in bladder cancer (BC), their prognostic value is not clearly established.
METHODS
METHODS
The present study aimed to quantify the TILs rates in BC, assess the derived immunoscore, and investigate their prognostic value. An immunochemistry-based quantification of the different subtypes of TILS was performed on paraffin-embedded blocks from patients with invasive urothelial carcinoma of the bladder. We have assessed the rates of TILs, respectively, on peri-tumoral (PT) and intra-tumoral (IT) areas and calculated for each case the corresponding IS which is the index: CD8+/CD3+ TILs. The IS was then classified as low (I0, I1) or high (I2, I3, I4). We included 30 cases in the analysis.
RESULTS
RESULTS
The median age of patients was 65 years with a sex ratio of 9. TILs densities and distribution were significantly variable between IT and PT areas CD3+ (p = 0.03) and CD8+ (p = 0.004) with the highest rates on the PT areas. In univariate analysis, a low density of CD8+ TILs was significantly associated with an advanced age (p = 0.05), with the presence of lympho-vascular invasion (p = 0.02) and with the absence of specific histological subtype (p = 0.05). A low immunoscore was significantly associated with the presence of lympho-vascular invasion (p = 0.004). No significant association was found between TILs subpopulations, the IS, and the other clinicopathological and survival data. The overall survival (OS) and disease-free survival (DFS) medians were slightly superior in highly T (CD3+/CD8+)-cell infiltrated tumors as well as tumors with a high IS densities. However, the univariate analysis showed that TILs and immunoscore did not impact overall survival (OS) and disease-free survival (DFS).
CONCLUSION
CONCLUSIONS
TILs and immunoscore might be effective prognostic tools in BC. However, standardized quantification methods and further investigation on larger samples are highly recommended to definitively attest the prognostic value of TILs and IS in BC.
Identifiants
pubmed: 38523233
doi: 10.1186/s43046-024-00212-8
pii: 10.1186/s43046-024-00212-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810.
doi: 10.1016/S0140-6736(16)30512-8
pubmed: 27345655
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306.
doi: 10.1038/nrc3245
pubmed: 22419253
Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25:261–7.
doi: 10.1016/j.coi.2013.03.004
pubmed: 23579076
Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8:327ra26.
doi: 10.1126/scitranslmed.aad6352
pubmed: 26912905
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.
doi: 10.1093/annonc/mdu450
pubmed: 25214542
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet. 2018;391:2128–39.
doi: 10.1016/S0140-6736(18)30789-X
Li X-D, Huang C-W, Liu Z-F, Jiang L-J, Chen J-W, Xie D, et al. Prognostic role of the immunoscore for patients with urothelial carcinoma of the bladder who underwent radical cystectomy. Ann Surg Oncol. 2019;26:4148–56.
doi: 10.1245/s10434-019-07529-y
pubmed: 31376036
Hülsen S, Lippolis E, Ferrazzi F, Otto W, Distel L, Fietkau R, et al. High stroma T-cell infiltration is associated with better survival in stage pT1 bladder cancer. Int J Mol Sci. 2020;21:8407.
doi: 10.3390/ijms21218407
pubmed: 33182484
pmcid: 7665154
Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
doi: 10.1186/1479-5876-10-205
pubmed: 23034130
pmcid: 3554496
Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Bayani J, Bartlett JMS, et al. Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer? Pathol - Res Pract. 2020;216:153200.
doi: 10.1016/j.prp.2020.153200
pubmed: 33022560
Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, et al. Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014;32:791–7.
doi: 10.1016/j.urolonc.2014.02.007
pubmed: 24794251
Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non–small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24:311–35. https://doi.org/10.1097/pap.0000000000000161 .
doi: 10.1097/pap.0000000000000161
pubmed: 28777143
pmcid: 5638696
Rouanne M, Betari R, Radulescu C, Goubar A, Signolle N, Neuzillet Y, et al. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. Eur J Cancer. 2019;108:111–9.
doi: 10.1016/j.ejca.2018.12.010
pubmed: 30654296
Wang B, Xie S, Bi J, Liu Z, Zeng H, Huang H, et al. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. Histopathol. 2019;75:354–64.
doi: 10.1111/his.13807
Wang B, Pan W, Yang M, Yang W, He W, Chen X, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110:489–98.
doi: 10.1111/cas.13887
pubmed: 30548363
Cao J, Yang X, Li J, Wu H, Li P, Yao Z, et al. Screening and identifying immune-related cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA Database and Bioinformatics. Front Oncol. 2020;9:1533.
doi: 10.3389/fonc.2019.01533
pubmed: 32010623
pmcid: 6974676
El Sissy C, Kirilovsky A, Van den Eynde M, Muşină A-M, Anitei M-G, Romero A, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. Off J Am Assoc Cancer Res. 2020;26:5198–207.
doi: 10.1158/1078-0432.CCR-20-0337
Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14:309–21.
doi: 10.1111/acel.12326
pubmed: 25720438
pmcid: 4406660
Krpina K, Babarović E, Jonjić N. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch. 2015;467:443–8.
doi: 10.1007/s00428-015-1808-6
pubmed: 26215559
Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci. 2007;104:3967–72.
doi: 10.1073/pnas.0611618104
pubmed: 17360461
pmcid: 1820692
Eich M-L, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, et al. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. Hum Pathol. 2019;89:24–32.
doi: 10.1016/j.humpath.2019.04.003
pubmed: 31026471
Lillesand M, Kvikstad V, Mangrud OM, Gudlaugsson E, van Diermen-Hidle B, Skaland I, et al. Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer. PLoS ONE 2020 [cité 2021 févr 4];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266352/
Masson-Lecomte A, Maillé P, Pineda S, Soyeux P, Sagrera A, Rava M, et al. CD8+ cytotoxic immune infiltrate in non-muscle invasive bladder cancer: a standardized methodology to study association with clinico-pathological features and prognosis. Bladder Cancer. 2019;5:159–69.
doi: 10.3233/BLC-180206
pubmed: 36157135
pmcid: 9503287
Haddad E. Evaluation of lymphocytic infiltration in urothelial carcinomas of the bladder and prognostic impact [Doctoral Dissertation]. Tunis: Faculty of Medicine of Tunis; 2021.
Liu K, Zhao K, Wang L, Sun E. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. Pathol - Res Pract. 2018;214:1074–80.
doi: 10.1016/j.prp.2018.05.010
pubmed: 29803657
Jóźwicki W, Brożyna AA, Siekiera J, Slominski AT. Changes in immunogenicity during the development of urinary bladder cancer: a preliminary study. Int. J. Mol. Sci. 2016 [cité 2021 mai 29];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813149/
Otto W, Denzinger S, Wieland WF, Hartmann A. First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. World J Urol. 2012;30:875–7.
doi: 10.1007/s00345-012-0974-2
pubmed: 23097035
Acs B, Ahmed FS, Gupta S, et al. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-13043-2 .
doi: 10.1038/s41467-019-13043-2
pubmed: 31784511
pmcid: 6884485